FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study showed Xolair significantly increased the amount of peanut, milk, egg and cashew it took to cause an allergic reaction17 million people in the U.S. have confirmed food allergies and more than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2,3Basel, 19 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted, under Priority Review, the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the reduction of allergic reactions, including anaphylaxis, that may occur with an accidental exposure to one or more foods in adult and paediatric patients aged 1 year and older with food allergy. If approved, people taking Xolair would still need to avoid foods they are allergic to (commonly referred to as “food avoidance”). The filing acceptance is based on positive interim analysis results from stage 1 of the National Institutes of Health (NIH)-sponsored pivotal phase III OUtMATCH study evaluating Xolair in patients allergic to peanuts and at least two other common foods. If approved, Xolair wou ld be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure. The FDA is ex...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Actemra | Allergy | Allergy & Immunology | Anaphylactic Shock | Arthritis | Asthma | Autoimmune Disease | Biotechnology | Cashew Nuts | Child Development | Children | Clinical Trials | Crohn's Disease | Cystic Fibrosis | Emergency Medicine | Epidemiology | Food Allergy | Food and Drug Administration (FDA) | Genetics | Grants | Hives | Immunotherapy | Infectious Diseases | Inflammatory Bowel Disease | International Medicine & Public Health | Internet | Japan Health | Men | Milk | National Institutes of Health (NIH) | Peanuts | Pediatrics | Pemphigus | Pharmaceuticals | Polyps | Rheumatoid Arthritis | Rheumatology | Rituxan | Study | Switzerland Health | Ulcerative Colitis | USA Health | Xolair